Hormone and Radiation Therapy for Prostate Cancer

(ARPEGGIO Trial)

This trial targets men with intermediate- or high-risk prostate cancer. It seeks to determine if special imaging during hormone therapy (Androgen Deprivation Therapy, or ADT) can help doctors target cancer more precisely with radiation. Participants will receive standard hormone therapy and radiation, along with three imaging scans over six months. Men diagnosed with prostate cancer who have undergone specific MRI and PET scans and have not yet started certain treatments might be suitable candidates. The trial aims to enhance the accuracy of future prostate cancer treatments and reduce side effects. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to advancements in prostate cancer care.

The trial information does not specify if you need to stop taking your current medications. However, you must be able to stop anti-coagulation medications for a procedure during the study.

Research shows that Androgen Deprivation Therapy (ADT) is generally safe, though it can cause some side effects. One study found that 43% of prostate cancer patients on ADT experienced major sexual problems. Another report noted that longer use of ADT is linked to more side effects in patients under 75. ADT's long history of use indicates it is well-researched.

For Stereotactic Body Radiation Therapy (SBRT), studies indicate it is mostly safe with a few side effects. About 10% of people might have stomach issues, and around 25% could experience some erectile dysfunction. Overall, SBRT has a good track record and is considered effective for treating prostate cancer.

Researchers are excited about this treatment for prostate cancer because it combines Androgen Deprivation Therapy (ADT) with Stereotactic Body Radiation Therapy (SBRT) and advanced PSMA PET/CT imaging. Unlike traditional treatments that might use standard radiation, SBRT delivers highly focused radiation doses, potentially improving precision and reducing side effects. The use of PSMA PET/CT imaging allows for better tumor visualization, enabling more targeted therapy. This innovative combination aims to enhance treatment effectiveness and offer a more personalized approach to managing prostate cancer.

Research has shown that Androgen Deprivation Therapy (ADT) effectively controls prostate cancer. One study found that about 59% of men experienced no disease progression five years after receiving ADT. Stereotactic Body Radiation Therapy (SBRT) also shows promising results. Studies indicate that around 95% of men treated with SBRT remained cancer-free after six years. In this trial, participants will receive a combination of ADT, SBRT, and PSMA PET/CT imaging, which have proven effective in treating prostate cancer, making them reliable options for managing the disease.⁵⁶⁷⁸⁹